Hugel Receives FDA Approval in the United States of Letybo for Injection
Hugel Receives U.S. FDA Approval for Its Botulinum Toxin Letybo
SEOUL, South Korea, Nov. 24, 2022 /PRNewswire/ -- Hugel, a global total medical aesthetics company (CEO: Ji-hoon Sohn), announced on November 24th that they obtained marketing approval for 50 and 100 units of its botulinum toxin called 'Letybo' for the indication of glabellar lines from the Therapeutic Goods Administration (TGA) of Australia on the 23rd (local time).
Hugel, a global total medical aesthetics company, announced that it resubmitted the BLA for its botulinum toxin called Botulax on October 6th, for the indication of glabellar lines to the US FDA.
Hugel, a global total medical aesthetics company (145020.KQ) announced its 2Q22 consolidated financial results on August 10th, recording a revenue of KRW67.4bn, operating profit of KRW22.3bn and net profit of KRW15.4bn.
Hugel, a global total medical aesthetics company, announces the publication of the phase 3 clinical trial for LetibotulinumtoxinA published by SCI-level international journal.
Hugel Co., Ltd. (CEO Son Ji-hoon), a global total medical aesthetics company, held a Board of Directors meeting on the 19th of May. Board resolved to convene an extraordinary general shareholders’ meeting to appoint Brent L. Saunders (the former CEO and Chairman of Allergan, now AbbVie) to the Board as a other non-executive director. Once his appointment is approved by shareholders’ meeting on June 29th, he will serve as the Chairman of Hugel’s Board.
FDA Issues form 483 to Hugel Inc.
Hugel America, Inc., a growth focused joint venture between aesthetic market-leading partners Hugel Inc., and Croma-Pharma GmbH, today announced that the Biologics License Application (BLA) for LetibotulinumtoxinA for Injection, to treat moderate to severe glabellar (frown) lines in adult patients has been accepted for review by the U.S. Food and Drug Administration (FDA).